Table 2.
Association between Characteristics at the Time of Macular Edema Diagnosis and Resolution of Macular Edema among Eyes with Uveitic Macular Edema in the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
| Characteristics | Number eyes | Percent resolved by 7 years (95% CI) | HR* | 95% CI* | P-value |
|---|---|---|---|---|---|
| Overall | 227 | 94 (89, 97) | |||
| Age, years | |||||
| <57 | 167 | 94 (87, 97) | 1.00 | ||
| ≥57 | 60 | 94 (85, 98) | 0.95 | 0.66, 1.51 | 0.77 |
| Gender, number | |||||
| Women | 166 | 95 (88, 98) | 1.00 | ||
| Men | 61 | 90 (79, 96) | 0.77 | 0.54, 1.09 | 0.14 |
| Race/ethnicity | |||||
| White, non-Hispanic | 131 | 93 (85, 96) | 1.00 | ||
| Black, non-Hispanic | 57 | 92 (81, 97) | 1.04 | 0.74, 1.47 | 0.81 |
| Hispanic/Other | 39 | 95 (83, 99) | 0.90 | 0.62, 1.30 | 0.58 |
| Uveitic anatomic class | |||||
| Intermediate uveitides | 105 | 92 (85, 96) | 1.00 | ||
| Posterior/panuveitides | 122 | 95 (86, 98) | 1.07 | 0.79, 1.46 | 0.64 |
| Macular edema diagnosis | |||||
| Prevalent (at baseline) | 143 | 93 (86, 97) | 1.00 | ||
| Incident (during follow-up) | 84 | 94 (85, 97) | 1.11 | 0.81, 1.51 | 0.64 |
| Uveitis duration, years | |||||
| ≤5 | 105 | 90 (71, 96) | 1.00 | ||
| >5 | 157 | 91 (81, 95) | 1.27 | 0.93, 1.75 | 0.14 |
| Inflammation activity at diagnosis macular edema | |||||
| Inactive | 69 | 92 (80, 96) | 1.00 | ||
| Active | 157 | 94 (88, 97) | 1.28 | 0.93, 1.75 | 0.13 |
| OCT† center point macular thickness (μm) | |||||
| <370 | 131 | 94 (88,97) | 1.00 | ||
| ≥370 | 95 | 93 (83, 97) | 0.99 | 0.93, 1,75 | 0.95 |
| OCT cystoid spaces | |||||
| Absent | 64 | 94 (85, 98) | 1.00 | ||
| Present | 156 | 93 (86, 96) | 1.20 | 0.91, 1.60 | 0.20 |
| Epiretinal membrane on OCT Overall comparison | |||||
| No | 120 | 97 (92, 99) | 1.00 | ||
| Yes | 102 | 89 (79, 94) | 0.74 | 0.55, 1.01 | 0.05 |
| Stratified by type ERM§ | |||||
| Prevalent | 0.58 | 0.38, 0.88 | 0.01 | ||
| Incident | 1.15 | 0.73, 1.80 | 0.55 | ||
| Lens status | |||||
| Phakic | 93 | 90 (80, 96) | 1.00 | ||
| Pseudophakic/aphakic | 134 | 96 (90, 98) | 1.19 | 0.86, 1.64 | 0.29 |
| Glaucoma medications | |||||
| No | 181 | 94 (88, 97) | 1.00 | ||
| Yes | 45 | 91 (75, 97) | 0.84 | 0.55, 1.27 | 0.41 |
| Prior glaucoma surgery | |||||
| No | 196 | 94 (88, 97) | 1.00 | ||
| Yes | 31 | 90 (72, 97) | 1.05 | 0.66, 1.66 | 0.84 |
| VA‡ worse than 20/40 | |||||
| Yes | 78 | 93 (82, 97) | 1.00 | ||
| No | 147 | 94 (88, 97) | 0.88 | 0.64, 1.19 | 0.40 |
| VA 20/200 or worse | |||||
| No | 194 | 93 (88, 96) | 1.00 | ||
| Yes | 31 | 96 (87, 99) | 0.83 | 0.57, 1.21 | 0.33 |
*
HR = unadjusted hazard ratio; HR’s >1.00 associated with faster resolution of macular edema; HR’s <1.00 associated with slower resolution of macular edema.
†
OCT = optical coherence tomography; results from different machines normalized to Zeiss Stratus scale.
‡
VA = visual acuity.
§
ERM = epiretinal membrane. Interaction p-value = 0.03.